Accuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023

4/13/23 4:30:00 PM ET

Medical/Dental Instruments

Health Care

Get the next $ARAY alert in real time by email

SUNNYVALE, Calif., April 13, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2023, ended March 31, 2023, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 26, 2023.

The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is (877) 344-7529 (USA) or (412) 317-0088 (international), conference ID: 3072079.

A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2023.

About Accuray

Accuray Incorporated (NASDAQ:ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Investor Contact

Aman Patel, CFA

Investor Relations, ICR-Westwicke

+1 (443) 450-4191

[email protected]

Media Contact

Beth Kaplan

Public Relations Director, Accuray

+1 (408) 789-4426

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2023-financial-results-on-april-26-2023-301797121.html

SOURCE Accuray Incorporated

Get the next $ARAY alert in real time by email

Date

Price Target

Rating

Analyst

2/13/2024

$9.00

Buy

ROTH MKM

6/23/2022

$7.50

Buy

B. Riley Securities

12/22/2021

$7.50

Buy

Loop Capital

Accuray to Report Third Quarter Fiscal 2023 Financial Results on April 26, 2023

Chat with this insight

Recent Analyst Ratings for $ARAY

$ARAY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 3,207 shares, decreasing direct ownership by 0.81% to 390,931 units (SEC Form 4)

Senior VP Global Operations Hoge Michael covered exercise/tax liability with 8,102 shares, decreasing direct ownership by 2% to 382,106 units (SEC Form 4)

President Winter Suzanne C covered exercise/tax liability with 16,604 shares, decreasing direct ownership by 1% to 1,336,476 units (SEC Form 4)

$ARAY SEC Filings

Accuray Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Accuray Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Accuray Incorporated

$ARAY Financials

Live finance-specific insights

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results

Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024

$ARAY Press Releases

Fastest customizable press release news feed in the world

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

Accuray Appoints Michael Murphy as VP, Corporate Controller

New England Journal of Medicine Study Reaffirms Five Session Radiation Treatment Provides Comparable Rates of Cancer Control, Tolerability and Sexual Functioning to Conventional Radiotherapy Treatment in Men with Localized Prostate Cancer

$ARAY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

SEC Form SC 13G filed by Accuray Incorporated

SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

$ARAY Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

$ARAY Market Insights

Live Market Insights

$ARAY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Long-term Customer Heidelberg University Hospital In Heidelberg, Germany, Has Selected Accuray's Radixact System, Equipped With ClearRT, Synchrony, And VOLO Ultra Optimizer Solutions, It Will Replace The Older Generation Accuray Tomotherapy System

Accuray Announced An Agreement With TrueNorth Medical Physics To Provide Radiation Oncology Departments With Third-party Support Designed To Enhance Their Department's Capabilities

Accuray's Precision Treatment System Gains Approval in China, Expanding Cancer Care Options

ROTH MKM initiated coverage on Accuray with a new price target

B. Riley Securities initiated coverage on Accuray with a new price target

Loop Capital initiated coverage on Accuray with a new price target

$ARAY Leadership Updates

Live Leadership Updates

Accuray Appoints Michael Murphy as VP, Corporate Controller

Robert C. Kill Joins Accuray Board of Directors

EDAP Appoints Medical Capital Equipment Finance Veteran Ken Mobeck as Chief Financial Officer of Company's U.S. Subsidiary

Recent Analyst Ratings for
$ARAY

$ARAY
Insider Trading

$ARAY
SEC Filings

$ARAY
Financials

$ARAY
Press Releases

$ARAY
Large Ownership Changes

$ARAY
Insider Purchases

$ARAY
Market Insights

$ARAY
Analyst Ratings

$ARAY
Leadership Updates